Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $203,000.

  • Stoke Therapeutics' Capital Expenditures rose 28.16% to $132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $480,000, marking a year-over-year increase of 23.08%. This contributed to the annual value of $203,000 for FY2024, which is 87.44% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Capital Expenditures of $203,000 as of FY2024, which was down 87.44% from $1.6 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Capital Expenditures peaked at $4.0 million during FY2022, and registered a low of $203,000 during FY2024.
  • For the 3-year period, Stoke Therapeutics' Capital Expenditures averaged around $1.9 million, with its median value being $1.6 million (2023).
  • As far as peak fluctuations go, Stoke Therapeutics' Capital Expenditures spiked by 212.71% in 2022, and later tumbled by 87.44% in 2024.
  • Yearly analysis of 5 years shows Stoke Therapeutics' Capital Expenditures stood at $1.1 million in 2020, then increased by 20.67% to $1.3 million in 2021, then skyrocketed by 212.71% to $4.0 million in 2022, then slumped by 59.21% to $1.6 million in 2023, then slumped by 87.44% to $203,000 in 2024.